Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company BioCancell Therapeutics Inc.
DescriptionPlasmid that activates the synthesis of diphtheria toxin in cancer cells expressing either the insulin-like growth factor-2 (IGF-2) or H19 gene
Molecular Target Insulin-like growth factor-2 (IGF-2) ; H19 gene
Mechanism of ActionGene therapy
Therapeutic ModalityGene therapy
Latest Stage of DevelopmentPreclinical
Standard IndicationBrain cancer
Indication DetailsTreat glioblastoma multiforme (GBM)
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today